BMS-936558 (MDX-1106)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for BMS-936558 (MDX-1106), covering 2015-10-20 to 2021-03-22. Get the full timeline:
Most recent: Clinical Trial Update: Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma [Phase 1]